Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
| Autor: | Xu Y; Evidera, Waltham, MA, 02451 USA., Fahrbach K; Evidera, Waltham, MA, 02451 USA., Dorman E; Evidera, Bethesda, MD, 20814 USA., Baculea S; Janssen-Cilag Ltd, High Wycombe, UK., Côté S; Janssen-Cilag Ltd, High Wycombe, UK., Sanden SV; Janssen-Cilag Ltd, Beerse, Belgium., Diels J; Janssen-Cilag Ltd, Beerse, Belgium. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of comparative effectiveness research [J Comp Eff Res] 2018 May; Vol. 7 (5), pp. 421-441. Date of Electronic Publication: 2017 Dec 06. |
| DOI: | 10.2217/cer-2017-0086 |
| Abstrakt: | Aim: A systematic literature review and network meta-analysis were conducted to determine the relative efficacy and safety of interventions for treatment-naive chronic lymphocytic leukemia patients, as comparative evidence is scarce. Materials & Methods: Relative treatment effects of progression-free survival, overall survival and safety outcomes were estimated via network meta-analysis based on data identified via systematic literature review. Results: Ibrutinib was superior in all pairwise comparisons for progression-free survival (probability to be better [P] range: overall population: 69-100%; fludarabine-ineligible population: 69-100%) and overall survival (P range: overall: 89-100%; fludarabine-ineligible: 91-100%) and had the highest probability of being best for all outcomes. Conclusion: Ibrutinib provides superior benefit in survival and safety compared with other front-line treatments of chronic lymphocytic leukemia. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|